HbA 1c is a valuable metric for comparing treatment groups in a randomized trial, for assessing glycemic trends in a population over time, or for cross-sectional comparisons of glycemic control in different populations. However, what is not widely appreciated is that HbA 1c may not be a good indicator of an individual patient's glycemic control because of the wide range of mean glucose concentrations and glucose profiles that can be associated with a given HbA 1c level. To illustrate this point, we plotted mean glucose measured with continuous glucose monitoring (CGM) versus central laboratory-measured HbA 1c in 387 participants in three randomized trials, showing that not infrequently HbA 1c may underestimate or overestimate mean glucose, sometimes substantially. Thus, if HbA 1c is to be used to assess glycemic control, it is imperative to know the patient's actual mean glucose to understand how well HbA 1c is an indicator of the patient's glycemic control. With knowledge of the mean glucose, an estimated HbA 1c (eA1C) can be calculated with the formula provided in this article to compare with the measured HbA 1c . Estimating glycemic control from HbA 1c alone is in essence applying a population average to an individual, which can be misleading. Thus, a patient's CGM glucose profile has considerable value for optimizing his or her diabetes management. In this era of personalized, precision medicine, there are few better examples with respect to the fallacy of applying a population average to a specific patient rather than using specific information about the patient to determine the optimal approach to treatment.
As expounded by Todd Rose in his book The End of Average (1), the mean of a measurement made among a large number of individuals is relevant for describing a population or group but often is not applicable for a given individual and can be misleading. Hemoglobin A 1c (HbA 1c ) provides a good example of this. HbA 1c , which reflects blood glucose concentrations over 3-4 months, is a valuable metric for comparing treatment groups in a randomized trial, for assessing glycemic trends in a population over time, or for cross-sectional comparisons of glycemic control in different populations, and it is the only metric of glycemic control that has been strongly associated with chronic diabetic vascular complications. However, it has been debated whether, for an individual patient, the HbA 1c level is the best marker for complication risk or whether the level of glycemia with which the HbA 1c is associated is an equal or better marker of the risk of complications. Well recognized is the fact that HbA 1c may not accurately reflect glycemic control in the presence of a hemoglobinopathy, hemolytic anemia, or other conditions that affect red blood cell life span or interfere with glucose binding to hemoglobin. However, what is not widely appreciated is that even when no such diagnosed condition is present, HbA 1c may not be a good indicator of an individual's glycemic control because of the wide range of mean glucose concentrations and glucose profiles that can be associated with a given HbA 1c level. It has been postulated that this mean glucoseHbA 1c discordance is due to interindividual variation in red blood cell life span (2, 3) .
This distinction in utilizing HbA 1c to compare groups versus its use in determining glycemic control for an individual was illustrated in a recent study we and others conducted assessing racial differences in the mean glucose-HbA 1c relationship (4) . The study showed that on average HbA 1c levels in blacks are about 0.4% (4.4 mmol/mol) higher than those of whites for a given mean glucose concentration determined with continuous glucose monitoring (CGM). However, importantly the data also showed that the interindividual variation in HbA 1c for a given mean glucose concentration within race substantially exceeds the average degree of variation between races.
The wide range of mean glucose concentrations associated with a given HbA 1c level is not a new observation. It has been known since at least the 1990 publication of Yudkin et al. (5) and has been consistently demonstrated in numerous studies in individuals with prediabetes, type 1 diabetes, and type 2 diabetes (6-13), including the A1c-Derived Average Glucose (ADAG) study, which produced the widely used conversion table to estimate mean glucose for an HbA 1c level (14).
The ADAG study was conducted in 2006-2007, utilizing CGM, which was not as accurate as current generation CGMs, as well as blood glucose meter measurements to determine the mean glucose concentration. The analysis was conducted on a data set with a median of 13 days of CGM measurements plus 39 days of fingerstick blood glucose measurements. To assess the mean glucoseHbA 1c relationship with current CGM technology and a greater amount of data, we pooled data collected in 387 participants (age range 20-78 years, 83% white, 315 with type 1 diabetes and 72 with type 2 diabetes) in three randomized trials using the Dexcom G4 Platinum CGM System with an enhanced algorithm, software 505 (Dexcom, Inc., San Diego, CA) (4, 15, 16) . Mean glucose concentration was determined for each participant using up to 13 weeks of CGM data (median amount of CGM data 66 days) and plotted versus HbA 1c measured following the collection of the CGM data at the Northwest Lipid Research Laboratories, University of Washington, Seattle, WA, using nonporous ion exchange highperformance chromatography (TOSOH, Biosciences, Inc., South San Francisco, CA).
As shown in Fig. 1 These results are quite similar to the results of the ADAG study ( 17) showed that a higher mortality rate was present only in the subjects in the intensive treatment group whose HbA 1c level was higher than the level predicted from fasting glucose concentration and that such subjects were more likely to have experienced severe hypoglycemia than those with an HbA 1c lower than predicted. Regardless of whether this finding is a possible explanation for the ACCORD mortality results, this analysis illustrates the problem and in some cases potential danger of determining a patient's treatment regimen and glycemia goal from HbA 1c alone without knowledge of the patient's mean glucose-HbA 1c relationship and glucose profile.
IMPLICATIONS FOR CLINICAL PRACTICE
The best way to determine whether a given HbA 1c might be over-or underestimating a patient's level of glycemic control is with CGM. CGM technology has advanced to where this can be done accurately and easily. For patients not already using CGM, a blinded CGM sensor could be worn once to compute a mean glucose concentration that can be compared with the patient's HbA 1c . Ideally CGM data should be obtained for at least 14 days immediately preceding the measurement of HbA 1c during a period when diabetes treatment and glycemic control are reasonably stable (18) . Several studies have demonstrated that an individual's mean glucose-HbA 1c relationship tends to be reasonably constant over time (7, (19) (20) (21) (22) . Although interval blinded CGM is useful for identifying patterns of glycemic control, a single blinded 14-day CGM wear to measure mean glucose concentration should be sufficient to estimate HbA 1c to determine how well the actual HbA 1c measurement estimates overall glycemic control for the patient. We recognize that this may not be realistic currently for all patients with diabetes, especially those with type 2 diabetes, but as sensor technology advances, that could become part of standard practice.
With knowledge of an individual's mean glucose concentration, a CGMestimated HbA 1c can be determined from the plot shown in Fig. 2 or by plugging the mean glucose concentration into the following formula: 3.38 + 0.02345 3 [mean glucose] (23,24). Then, to inform how well an HbA 1c measurement estimates the mean glucose concentration for a patient, the estimated HbA 1c (eA1C) can be compared with the observed HbA 1c , which has been referred to as the hemoglobin glycation index (observed HbA 1c minus predicted HbA 1c ) (9) .
While potentially better than HbA 1c in understanding an individual patient's glycemic control, mean glucose itself is an average, and different degrees of glycemic variability and many different glycemic patterns could produce similar mean glucose concentrations and similar HbA 1c levels. Figure 3 shows 2 weeks of CGM data (up to 288 sensor glucose measurements/day) displayed as a modal day or an ambulatory glucose profile (AGP) for four patients with type 1 diabetes using multiple daily injections of insulin. While each patient has a central laboratorymeasured HbA 1c of 8%, the AGP glucose patterns vary greatly and would each lead to different clinical advice for lifestyle changes or insulin adjustments. This is where retrospective review of CGM data has considerable benefit. CGM profiles provide far more information than just the mean glucose concentration by identifying patterns of hyperglycemia and hypoglycemia as well as potentially dangerous high or low glucose concentrations that are often missed with selfmonitoring of blood glucose. (25, 26) that found an association between hypoglycemia and cardiovascular events emphasize the importance of understanding a patient's glucose profile with CGM to potentially identify patients who may be at high risk for these events. Thus CGM by providing more clinical insights than HbA 1c or self-monitoring of blood glucose measurements can help optimize and personalize glucose control and diabetes management (27).
CONCLUSIONS
We have written this Perspective to raise awareness of the need to know a patient's actual mean glucose concentration, ideally by using CGM, if HbA 1c is to be used to assess a patient's glycemic control and make diabetes management decisions. As long as HbA 1c is being used to define a glycemic target, we hope that eA1C becomes a standard metric used by clinicians and patients in assessing the level of glycemic control. Beyond that, a patient's CGM glucose profile, or AGP, has considerable value for optimizing diabetes management. Estimating glycemic control from HbA 1c alone is in essence applying a population average to an individual, which can be misleading. In this era of personalized, precision medicine, there are few better examples than this one with respect to the fallacy of applying a population average to a specific patient rather than using specific information about the patient to determine the optimal approach to treatment. 
